Navigation Links
M. D. Anderson examines use of toad venom in cancer treatment
Date:9/24/2009

HOUSTON - Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center.

The results from the Phase I clinical study, a collaborative research project between M. D. Anderson and Fudan University Cancer Hospital in Shanghai, are reported in the online Early View feature of the journal Cancer. The study marks the first time a formal clinical trial has examined the relationship between huachansu dose and toxicity, although the drug is common in China and approved by the Chinese Food and Drug Administration.

Huachansu is widely used to treat patients with liver, lung, colon and pancreatic cancer at oncology clinics in China. Chinese clinical trials conducted since the 1970s have demonstrated the anti-cancer properties of huachansu, citing total response rates of 10 percent and 16 percent observed in patients with advanced hepatocellular carcinoma and lung cancer, respectively1,2.

"Studying traditional Chinese medicine such as huachansu is new to American research institutions, which have been skeptical and slow to adopt these complementary treatments. However, it is important to understand its potential role in treating cancer," says Lorenzo Cohen, Ph.D., one of the paper's authors and director of the Integrative Medicine Program at M. D. Anderson. "We wanted to apply a Western medicine-based approach to explore the role of the toad venom compound in cancer patients and test if it is possible to deliver a more potent dose without raising toxicities or side effects."

The clinical trial was conducted at the Fudan University Cancer Hospital while M. D. Anderson provided training and ongoing consultation. The institutions collaboratively designed the trial that was approved by both institutional review boards. M. D. Anderson and Fudan University Cancer Hospital signed a sister institution agreement in 2003, creating a framework for research, educational and clinical collaboration.

The typical dose of huachansu used in China is approximately 15 milliliters of drug per meter squared of body mass (mL/m2). In the study, 15 patients with stage III or IV hepatocellular (liver) carcinoma, nonsmall cell lung cancer or pancreatic cancer received one of five dose levels ranging from 10 mL/ m2 up to 90 mL/m2 from January 2005 through July 2006. The treatment was repeated daily for 14 days followed by seven days off (one cycle). After two cycles, most patients received other treatments. Quality control methods were put in place to ensure huachansu of a uniform and consistent lot.

While the dose was up to eight times higher than conventional doses used in China, researchers observed only low toxicities or side effects. Eleven (73 percent) patients had no toxicities greater than the lowest grade measured. Importantly, no significant cardiac toxicity was observed and no significant changes in cancer-related symptoms occurred. Of the 15 patients who completed the treatment, six hepatocellular carcinoma patients (40 percent) had stable disease for a median of six months. One patient had a 20 percent reduction in tumor mass that lasted for more than 11 months.

"Even though we saw no complete or partial response (reduction of disease by 30 percent or more) it is encouraging that the cancer did not progress in a large set of the hepatocellular carcinoma patients," says Zhiqiang Meng, principal investigator on the trial and an associate professor and deputy chair of the Department of Integrative Oncology at Fudan University Cancer Hospital, "Previous observations from studies conducted in China have shown that huachansu can inhibit tumor cell growth and improve immunologic function3. These findings, coupled with that knowledge, demonstrate the need for further clinical trials of this promising agent."

A Phase II clinical trial comparing the effects of huachansu combined with gemcitabine (Gemzar) to gemcitabine and placebo for patients with advanced pancreatic cancer is under way at the Fudan University Cancer Hospital in collaboration with M. D. Anderson.


'/>"/>

Contact: Lindsay Anderson
lindsay.anderson@gabbe.com
212-220-4444
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. M.D. Anderson-led team reports possible key to autoimmune disease
2. UCI Medical Affiliates Inc. Opens a New Doctors Care Center in Anderson
3. M. D. Anderson-Prevention poll finds women can do more to prevent cancer...but arent
4. M. D. Anderson-Prevention poll finds women can do more to prevent cancer ... but arent
5. M. D. Anderson researchers identify tumor-suppressor gene for lung cancer
6. SEIU Endorses Anderson, Perea, and Perea in Fresno
7. M. D. Anderson research links diet, gardening and lung cancer risk
8. CyberKnife Centers of Miami, Palm Beach and Tampa Invited to Join M.D. Anderson Cancer Center Study
9. Naviscan PET Systems to Place High-Resolution PET Scanner at M. D. Anderson Cancer Center
10. M. D. Anderson nurses find empowerment in PACTs
11. M. D. Anderson nurse addresses lymphedema in breast cancer patients and survivors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... Falls Church, VA (PRWEB) , ... September 21, ... ... **An FDAnews Webinar**, Sept. 26, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... exacting business. It’s easy to get things wrong, run afoul of The Quality ...
(Date:9/21/2017)... CA (PRWEB) , ... September 21, 2017 , ... ... lunch and learn with Infinity Behavioral Health Services for professionals in the addiction ... a Commercial Payer Audit . , Insurance companies and state and federal ...
(Date:9/21/2017)... IL. (PRWEB) , ... September 21, 2017 , ... ... results released today of a new member survey conducted by the International ... restoration procedures performed from 2014 to 2016 rose 60 percent, with 635,189 procedures ...
(Date:9/21/2017)... San Diego, Ca (PRWEB) , ... September 21, 2017 , ... ... and affordable services to its customers, and give back to the community. For over ... on of the most successful companies serving plumbing in San Diego. They ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in Chicago, IL ... life-sciences industry for ensuring label quality and improving patient safety. , ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... ORANGEBURG, N.Y. , Sept. 6, 2017   PDI ... today announced it will host an educational session focused ... line-associated bloodstream infection (CLABSI) prevention at the 2017 Annual ... meeting, which will take place at the ... Arizona from Sept. 16-19, will also feature ...
(Date:9/5/2017)... Inc. has announced another milestone in their continued growth and success of the ... demands of customer engagements regionally.  ... office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office ... In addition ...
(Date:9/1/2017)... Michael Penna , President and CEO ... for growth in his response to the July 13, ... seeking a buyer for eMDs. Penna,s company, Complete HealthCare ... Value Added Reseller and national leader in the independent ... "As the healthcare market continues to dictate consolidation, healthcare ...
Breaking Medicine Technology: